<DOC>
	<DOCNO>NCT01774344</DOCNO>
	<brief_summary>This clinical study evaluate efficacy safety regorafenib patient advance liver cancer progress sorafenib treatment . Approximately 560 patient meet entry criterion randomly assign 2:1 ratio regorafenib placebo ( 1/3 chance receive placebo ) . Primary endpoint study overall survival .</brief_summary>
	<brief_title>Study Regorafenib After Sorafenib Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>Regorafenib BAY73-4506</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Histological cytological confirmation HCC ( hepatocellular carcinoma ) noninvasive diagnosis HCC per American Association Study Liver Diseases criterion patient confirm diagnosis cirrhosis Barcelona Clinic Liver Cancer stage Category B C benefit treatment establish efficacy high priority resection , local ablation , chemoembolization systemic sorafenib . Failure prior treatment sorafenib ( define document radiological progression accord radiology charter ) . Randomization need perform within 10 week last treatment sorafenib . Tolerability prior treatment sorafenib define less 20 day minimum daily dose 400 mg QD within last 28 day prior withdrawal . Liver function status ChildPugh Class A . Child Pugh status calculate base clinical finding laboratory result screen period . Local locoregional therapy intrahepatic tumor lesion ( e.g . surgery , radiation therapy , hepatic arterial embolization , chemoembolization , radiofrequency ablation , percutaneous ethanol injection , cryoablation ) must complete &gt; /=4 week first dose study medication . Note : patient receive sole intrahepatic intraarterial chemotherapy , without lipiodol embolizing agent eligible . Eastern Cooperative Oncology Group Performance Status 0 1 . Adequate bone marrow , liver renal function assess follow laboratory test conduct within 7 day randomization . Glomerular filtration rate &gt; /= 30 ml/min/1.73 m2 accord Modification diet renal disease study equation . At least one unidimensional measurable lesion compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord RECIST ( RECIST version 1.1 ) , modify RECIST HCC . Tumor lesion situate previously irradiate area , area subject locoregional therapy , may consider measurable demonstrated progression lesion . Life expectancy least 3 month . Women childbearing potential men must agree use adequate contraception . Exclusion Criteria : Sorafenib treatment within 2 week randomization . Prior systemic treatment HCC , except sorafenib . Permanent discontinuation prior sorafenib therapy due sorafenib related toxicity . Known history symptomatic metastatic brain meningeal tumor ( head CT MRI screen confirm absence central nervous system [ CNS ] disease patient symptom suggestive consistent CNS disease ) . Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) . Uncontrolled ascites ( define easily control diuretic paracentesis treatment ) . Ongoing infection &gt; Grade 2 accord NCICTCAE ( National Cancer Institute Common Terminology Criteria Adverse Events ) v. 4.0 . Hepatitis B allow active replication present . Hepatitis C allow antiviral treatment require . Clinically significant bleeding NCICTCAE version 4.0 Grade 3 high within 30 day randomization . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication . Patients unable swallow oral medication . Interstitial lung disease ongoing sign symptoms time screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>BAY73-4506</keyword>
</DOC>